Patent · US Active

Soluble tumor necrosis factor receptor mutant

US8454969B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignees

SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO., LTD. · CN
Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd. · CN

Inventors

Yanjun Liu · Shanghai, CN
Tong YANG · Shanghai, CN
Yijun SHEN · Shanghai, CN
Jinsong Wu · Wilmette, US
Fang WU · Shanghai, CN

Key dates

Filing date	Jan 12, 2009
Grant date	Jun 4, 2013
Priority date	—
Expiry date	Apr 4, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A soluble tumor necrosis factor receptor 2 (TNFRII) mutant has an amino acid substitution at position 92Glu compared with the wild TNFRII. The mutant improves the cytotoxicity capacity of neutralizing TNFalpha and lymphotoxin. The mutant and fusion protein comprising it are useful for the treatment of TNFalpha and lymphotoxin related diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.